{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:55:48Z","timestamp":1767988548915,"version":"3.49.0"},"reference-count":46,"publisher":"Mark Allen Group","issue":"Sup21b","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Nurs"],"published-print":{"date-parts":[[2025,11,19]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Thalassaemia is a severe inherited haemoglobin disorder that requires lifelong blood transfusions. In transfusion-dependent thalassaemia, continuous iron chelation therapy is essential to prevent organ damage from iron overload. Subcutaneous desferrioxamine has historically been the cornerstone of chelation but imposes a heavy treatment burden, with adherence often compromised by pain, fatigue and psychosocial strain. More recently, the evolution of infusion devices, from traditional butterfly needles to smaller-gauge needles such as Neria\n                      <jats:sup>\u2122<\/jats:sup>\n                      (previously marketed as Thalaset) and the cannula-based Neria\n                      <jats:sup>\u2122<\/jats:sup>\n                      Guard, has aimed to improve patient comfort and treatment concordance. However, little is known about how these device changes have shaped patient and caregiver experiences in the UK.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This evaluation work employed a mixed-methods design, combining a structured survey with open-ended qualitative questions in addition to interview feedback. Participants included patients and carers with direct experience of subcutaneous desferrioxamine therapy across different age groups. Quantitative data were analysed descriptively, while qualitative responses were examined thematically to capture lived experiences, psychosocial impacts and perspectives on device usability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Device choice emerged as a key determinant of treatment concordance. Traditional butterfly needles were strongly associated with pain, skin reactions, sleep disruption and reduced willingness to initiate infusions. In contrast, Neria and Neria Guard were consistently described as more comfortable, less traumatic and easier to integrate into daily routines. Participants reported that reduced discomfort improved their confidence, independence and overall quality of life. Carers, particularly parents administering therapy to children, described less emotional strain when using newer devices. Nonetheless, adherence challenges persisted, especially among adolescents and young adults, reflecting ongoing psychosocial barriers, such as treatment fatigue and stigma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The evolution of subcutaneous infusion devices has had a tangible impact on patient and carer experiences in thalassaemia. While newer devices reduce physical discomfort and support greater concordance, the broader psychosocial burden of lifelong chelation remains considerable. Findings highlight the importance of patient-centred device design and the need for holistic support strategies that address both the technical and emotional dimensions of chronic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Disclaimer<\/jats:title>\n                    <jats:p>This study was sponsored by Convatec; however, Convatec did not influence the study design, and the discussions, conclusions and interpretation of results in this manuscript are solely the opinion of the author.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.12968\/bjon.2025.34.sup21b.s1","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:54:46Z","timestamp":1767970486000},"page":"S1-S19","source":"Crossref","is-referenced-by-count":0,"title":["Concordance, comfort and care: how advances in subcutaneous infusion needle design are transforming thalassaemia treatment in the UK"],"prefix":"10.12968","volume":"34","author":[{"given":"Roanna","family":"Maharaj","sequence":"first","affiliation":[{"name":"Director, Trinity Health Agency Limited"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5130","reference":[{"issue":"6","key":"B1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1442-200X.2007.02482.x","volume":"49","author":"Aydinok Y","year":"2007","journal-title":"Pediatr Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/2159676X.2019.1628806"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"B4","unstructured":"British Psychological Society. Code of human research ethics. 2014. https:\/\/cms.bps.org.uk\/sites\/default\/files\/2022-06\/BPS%20Code%20of%20Human%20Research%20Ethics%20%281%29.pdf (accessed 19 September 2025)"},{"key":"B5","unstructured":"Cappellini MD, Cohen A, Eleftheriou A et al. Thalassaemia International Federation guidelines for the clinical management of thalassaemia, 2nd edn. 2008. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK173968\/ (accessed 19 September 2025)"},{"key":"B6","doi-asserted-by":"crossref","first-page":"100646","DOI":"10.1016\/j.blre.2019.100646","volume":"41","author":"Cappellini MD","year":"2020","journal-title":"Blood Rev"},{"issue":"6","key":"B7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2165\/00003495-200969060-00007","volume":"69","author":"Cappellini MD","year":"2009","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20103"},{"issue":"2","key":"B9","first-page":"120","volume":"26","author":"Clarke V","year":"2013","journal-title":"Psychologist"},{"key":"B10","unstructured":"Convatec. Instructions for Use for the Neria\u2122 product range of infusion sets. 2023. https:\/\/www.convatec.com\/en-gb\/infusion-care\/product-education\/overall-neria-ifus (accessed 4 November 2025)"},{"issue":"3","key":"B11","first-page":"124","volume":"125","author":"Cooley J","year":"2011","journal-title":"Acta Haematol"},{"key":"B12","unstructured":"Creswell JW, Plano Clark VL. Designing and conducting mixed methods research. 3rd edn. New York (NY): Sage; 2018"},{"issue":"1","key":"B13","doi-asserted-by":"crossref","first-page":"e2013068","DOI":"10.4084\/mjhid.2013.068","volume":"5","author":"de Sanctis V","year":"2013","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"6","key":"B14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1524-4733.2007.00202.x","volume":"10","author":"Delea TE","year":"2007","journal-title":"Value Health"},{"issue":"6","key":"B15","first-page":"561","volume":"38","author":"Delea TE","year":"2020","journal-title":"PharmacoEconomics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S269352"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S269352"},{"issue":"1","key":"B18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/pho.21.1.27.35","volume":"21","author":"Farmaki K","year":"2004","journal-title":"Pediatr Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.33590\/emjhematol\/20-00249"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21474"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.51847\/LXofvYDvl2"},{"key":"B22","author":"Lee J","year":"2024","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-023-02221-y"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/0147-1767(85)90062-8"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.951947"},{"issue":"6","key":"B26","first-page":"1545","volume":"106","author":"Musallam KM","year":"2021","journal-title":"Haematologica"},{"key":"B27","unstructured":"National Haemoglobinopathy Register. Annual report 2023. 2024. https:\/\/nhr.mdsas.com\/wp-content\/uploads\/2024\/09\/NHR-Annual-Report-23-24.pdf (accessed 19 September 2025)"},{"key":"B28","unstructured":"NHS England. Patient and public participation policy. 2021. https:\/\/www.england.nhs.uk\/publication\/patient-and-public-participation-policy\/ (accessed 19 September 2025)"},{"key":"B29","unstructured":"National Institute for Health and Care Excellence. Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over. 2024. https:\/\/www.nice.org.uk\/guidance\/ta1003 (accessed 11 November 2025)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/1609406917733847"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.739"},{"key":"B32","unstructured":"Patton MQ. Qualitative research & evaluation methods. 4th edn. New York (NY): Sage; 2015"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31829b2be6"},{"issue":"8","key":"B34","first-page":"580","volume":"84","author":"Porter J","year":"2009","journal-title":"Am J Hematol"},{"key":"B35","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/blood-2018-99-110885","volume":"132","author":"Porter J","year":"2018","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.361"},{"issue":"3","key":"B37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.hoc.2019.01.002","volume":"33","author":"Porter JB","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"B38","first-page":"75","volume":"18","author":"Reddy PS","year":"2022","journal-title":"Ther Clin Risk Manag"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802160834"},{"issue":"9","key":"B40","first-page":"1187","volume":"91","author":"Telfer P","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"B41","first-page":"201","volume":"200","author":"Telfer P","year":"2023","journal-title":"Br J Haematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4135\/9781526405555.n2"},{"key":"B43","unstructured":"UK Thalassaemia Society. Standards for the clinical care of adults and children with thalassaemia in the UK, 4th edn. 2023. https:\/\/haemoglobin.org.uk\/wp-content\/uploads\/2024\/01\/standards-for-the-clinical-care-of-children-and-adults-living-with-thalassaemia-in-the-uk-4th-edition-2023.pdf (accessed 19 September 2025)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.5430\/jnep.v6n5p100"},{"issue":"12","key":"B45","first-page":"1161","volume":"19","author":"Vekeman F","year":"2016","journal-title":"J Med Econ"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-251348"}],"container-title":["British Journal of Nursing"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.magonlinelibrary.com\/doi\/pdf\/10.12968\/bjon.2025.34.Sup21b.S1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:54:50Z","timestamp":1767970490000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.magonlinelibrary.com\/doi\/10.12968\/bjon.2025.34.Sup21b.S1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":46,"journal-issue":{"issue":"Sup21b","published-print":{"date-parts":[[2025,11,19]]}},"alternative-id":["10.12968\/bjon.2025.34.Sup21b.S1"],"URL":"https:\/\/doi.org\/10.12968\/bjon.2025.34.sup21b.s1","relation":{},"ISSN":["0966-0461","2052-2819"],"issn-type":[{"value":"0966-0461","type":"print"},{"value":"2052-2819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}